Brad R Rocco1, Adam M DeDionisio1, David A Lewis2, Kenneth N Fish3. 1. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department Neuroscience, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: fishkn@upmc.edu.
Abstract
BACKGROUND: The axons of chandelier cells (ChCs) target the axon initial segment of pyramidal neurons, forming an array of boutons termed a cartridge. In schizophrenia, the density of cartridges detectable by gamma-aminobutyric acid (GABA) membrane transporter 1 immunoreactivity is lower, whereas the density of axon initial segments detectable by immunoreactivity for the α2 subunit of the GABAA receptor is higher in layers 2/superficial 3 of the prefrontal cortex. These findings were interpreted as compensatory responses to lower GABA levels in ChCs. However, we recently found that in schizophrenia, ChC cartridge boutons contain normal levels of the 67 kDa isoform of glutamic acid decarboxylase (GAD67) protein, the enzyme responsible for GABA synthesis in these boutons. To understand these findings we quantified the densities of ChC cartridges immunoreactive for vesicular GABA transporter (vGAT+), which is present in all cartridge boutons, and the subset of cartridges that contain calbindin (CB+). METHODS: Prefrontal cortex tissue sections from 20 matched pairs of schizophrenia and unaffected comparison subjects were immunolabeled for vGAT, GAD67, and CB. RESULTS: The mean density of vGAT+/CB+ cartridges was 2.7-fold higher, exclusively in layer 2 of schizophrenia subjects, whereas the density of vGAT+/CB- cartridges did not differ between subject groups. Neither vGAT, CB, or GAD67 protein levels per ChC bouton nor the number of boutons per cartridge differed between subject groups. CONCLUSIONS: Our findings of a greater density of CB+ ChC cartridges in prefrontal cortex layer 2 from schizophrenia subjects suggests that the normal developmental pruning of these cartridges is blunted in the illness.
BACKGROUND: The axons of chandelier cells (ChCs) target the axon initial segment of pyramidal neurons, forming an array of boutons termed a cartridge. In schizophrenia, the density of cartridges detectable by gamma-aminobutyric acid (GABA) membrane transporter 1 immunoreactivity is lower, whereas the density of axon initial segments detectable by immunoreactivity for the α2 subunit of the GABAA receptor is higher in layers 2/superficial 3 of the prefrontal cortex. These findings were interpreted as compensatory responses to lower GABA levels in ChCs. However, we recently found that in schizophrenia, ChC cartridge boutons contain normal levels of the 67 kDa isoform of glutamic acid decarboxylase (GAD67) protein, the enzyme responsible for GABA synthesis in these boutons. To understand these findings we quantified the densities of ChC cartridges immunoreactive for vesicular GABA transporter (vGAT+), which is present in all cartridge boutons, and the subset of cartridges that contain calbindin (CB+). METHODS: Prefrontal cortex tissue sections from 20 matched pairs of schizophrenia and unaffected comparison subjects were immunolabeled for vGAT, GAD67, and CB. RESULTS: The mean density of vGAT+/CB+ cartridges was 2.7-fold higher, exclusively in layer 2 of schizophrenia subjects, whereas the density of vGAT+/CB- cartridges did not differ between subject groups. Neither vGAT, CB, or GAD67 protein levels per ChC bouton nor the number of boutons per cartridge differed between subject groups. CONCLUSIONS: Our findings of a greater density of CB+ ChC cartridges in prefrontal cortex layer 2 from schizophrenia subjects suggests that the normal developmental pruning of these cartridges is blunted in the illness.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Y Jiao; Z Sun; T Lee; F R Fusco; T D Kimble; C A Meade; S Cuthbertson; A Reiner Journal: J Neurosci Methods Date: 1999-11-15 Impact factor: 2.390
Authors: John F Enwright; Sowmya Sanapala; Aaron Foglio; Raissa Berry; Kenneth N Fish; David A Lewis Journal: Neuropsychopharmacology Date: 2016-02-12 Impact factor: 7.853
Authors: Thomas M Hyde; Barbara K Lipska; Towhid Ali; Shiny V Mathew; Amanda J Law; Ochuko E Metitiri; Richard E Straub; Tianzhang Ye; Carlo Colantuoni; Mary M Herman; Llewellyn B Bigelow; Daniel R Weinberger; Joel E Kleinman Journal: J Neurosci Date: 2011-07-27 Impact factor: 6.167
Authors: T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis Journal: Mol Psychiatry Date: 2007-05-01 Impact factor: 15.992
Authors: Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis Journal: Am J Psychiatry Date: 2008-02-15 Impact factor: 18.112
Authors: Ahmad Alhourani; Kenneth N Fish; Thomas A Wozny; Vivek Sudhakar; Ronald L Hamilton; R Mark Richardson Journal: J Neurophysiol Date: 2019-12-04 Impact factor: 2.714
Authors: Kenneth N Fish; Brad R Rocco; Adam M DeDionisio; Samuel J Dienel; Robert A Sweet; David A Lewis Journal: Biol Psychiatry Date: 2021-02-19 Impact factor: 12.810
Authors: Jeroen C de Jonge; Christiaan H Vinkers; Hilleke E Hulshoff Pol; Anouk Marsman Journal: Front Psychiatry Date: 2017-08-11 Impact factor: 4.157